Naveed Sattar1, Allan Gaw1, Olga Scherbakova1, Ian Ford1, Denis St J O’Reilly1, Steven E. Kahn1, Chris Isles1, Peter W. Macfarlane1, Chris J. Packard1, Stuart M. Cobbe1, James Shepherd1
1From the University Departments of Pathological Biochemistry (N.S., D.J.O.R., C.J.P., J.S.), Clinical Trials Unit (A.G.), Division of Cardiovascular and Medical Sciences (P.W.M., S.M.C.), Glasgow Royal Infirmary, Glasgow, UK; Robertson Centre for Biostatistics (O.S., I.F.), University of Glasgow, Glasgow, UK; Department of Medicine (S.M.H.), University of Texas Health Science Center at San Antonio; and Department of Medicine (C.I.), Dumfries and Galloway District General Hospital, Dumfries, Scotland.
Tóm tắt
Background—
The National Cholesterol Education Program (NCEP) recently proposed a simple definition for metabolic syndrome. Information on the prospective association of this definition for coronary heart disease (CHD) and type 2 diabetes is currently limited.
Methods and Results—
We used a modified NCEP definition with body mass index in place of waist circumference. Baseline assessments in the West of Scotland Coronary Prevention Study were available for 6447 men to predict CHD risk and for 5974 men to predict incident diabetes over 4.9 years of follow-up. Mean LDL cholesterol was similar but C-reactive protein was higher (
P
<0.0001) in the 26% of men with the syndrome compared with those without. Metabolic syndrome increased the risk for a CHD event [univariate hazard ratio (HR)=1.76 (95% CI, 1.44 to 2.15)] and for diabetes [univariate HR=3.50 (95% CI 2.51 to 4.90)]. Metabolic syndrome continued to predict CHD events (HR=1.30, 95% CI, 1.00 to 1.67,
P
=0.045) in a multivariate model incorporating conventional risk factors. Men with 4 or 5 features of the syndrome had a 3.7-fold increase in risk for CHD and a 24.5-fold increase for diabetes compared with men with none (both
P
<0.0001). C-reactive protein enhanced prognostic information for both outcomes. With pravastatin, men with the syndrome had similar risk reduction for CHD as compared with those without (HR, 0.73 and 0.69; pravastatin versus placebo).
Conclusions—
A modified NCEP metabolic syndrome definition predicts CHD events, and, more strikingly, new-onset diabetes, and thus helps identify individuals who may receive particular benefit from lifestyle measures to prevent these diseases.
